Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Accuray Buys TomoTherapy To Create 'Premier' Radiation Oncology Company

This article was originally published in The Gray Sheet

  • News

Executive Summary

Radiosurgery device maker Accuray is acquiring radiation therapy developer TomoTherapy for $277 million in cash and stock to form “the premier radiation oncology company,” according to the firms.

You may also be interested in...



People Briefs: Encision, Solta, Chembio, Accuray, Devon and FDA

Encision CEO Fred Perner dead at 59. Solta Medical CEO resigns. Chembio president and CEO announces he will retire in May. FDA gains permanent regulatory affairs chief. More people news.

People In Brief

Accuray, Svelte Medical Systems and Sonoma Orthopedics get new CEOs, and more personnel news from device companies.

New Products In Brief

St. Jude Medical’s Ilumien

Table

View full table

Related Content

In Vivo
Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT029923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By